Pathophysiology of Overactive Bladder

LUTS: Lower Urinary Tract Symptoms

Volumn 4, Issue SUPPL. 1, 2012, Pages 48-55

  Meng, En ^a   Lin, Wei Yu ^b   Lee, Wei Chia ^b   Chuang, Yao Chi ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Inflammation; Metabolic syndrome; Overactive bladder; Pathophysiology; Urothelium

Indexed keywords

CHEMOKINE; NERVE GROWTH FACTOR; PROSTAGLANDIN E2;

BLADDER NECK STENOSIS; DETRUSOR MUSCLE; DIABETES MELLITUS; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; NERVE EXCITABILITY; NOCTURIA; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUALITY OF LIFE; REVIEW; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; UROTHELIUM;

EID: 84863389401     PISSN: 17575664     EISSN: 17575672     Source Type: Journal    
DOI: 10.1111/j.1757-5672.2011.00122.x     Document Type: Review

References (104)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the standardization sub-committee of the international continence society. Neurourol Urodyn 2002; 21: 167-78.
2. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108: 1132-8 [Epub ahead of print].
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15.
4. Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol 2007; 17: 231-6.
5. Brading AF. Acetylcholine and the overactive bladder. Eur Urol 2007; 51: 881-3.
6. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
7. Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50: 57-67; discussion 68-73.
8. Brading A. Overactive bladder: why it occurs. Women's Health Med 2005; 2: 20-3.
9. Brading AF, Symes S. Ischemia as an etiological factor in bladder instability: implications for therapy. Adv Exp Med Biol 2003; 539: 255-69.
10. German K, Bedwani J, Davies J, Brading AF, Stephenson TP. Physiological and morphometric studies into the pathophysiology of detrusor hyperreflexia in neuropathic patients. J Urol 1995; 153: 1678-83.
11. Mills IW, Greenland JE, McMurray G et al. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 2000; 163: 646-51.
12. Sibley GN. Developments in our understanding of detrusor instability. Br J Urol 1997; 80(Suppl 1): 54-61.
13. Sui G, Fry CH, Malone-Lee J, Wu C. Aberrant Ca2+ oscillations in smooth muscle cells from overactive human bladders. Cell Calcium 2009; 45: 456-64.
14. de Groat WC. A neurologic basis for the overactive bladder. Urology 1997; 50: 36-52; discussion 53-56.
15. Kessler TM, Burkhard FC, Z'Brun S et al. Effect of thalamic deep brain stimulation on lower urinary tract function. Eur Urol 2008; 53: 607-12.
16. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn 2008; 27: 466-74.
17. O'Reilly BA, Kosaka AH, Knight GF et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002; 167: 157-64.
18. Yoshimura N. Lower urinary tract symptoms (LUTS) and bladder afferent activity. Neurourol Urodyn 2007; 26: 908-13.
19. Yamaguchi O, Honda K, Nomiya M et al. Defining overactive bladder as hypersensitivity. Neurourol Urodyn 2007; 26: 904-7.
20. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006; 25: 156-61.
21. Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316, 243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 2010; 29: 771-6.
22. Hougaard C, Fraser MO, Chien C et al. A positive modulator of K Ca 2 and K Ca 3 channels, 4, 5-dichloro-1, 3-diethyl-1, 3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo. J Pharmacol Exp Ther 2009; 328: 28-39.
23. Maggi CA, Santicioli P, Parlani M, Astolfi M, Patacchini R, Meli A. The presence of mucosa reduces the contractile response of the guinea-pig urinary bladder to substance P. J Pharm Pharmacol 1987; 39: 653-5.
24. Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007; 4: 46-54.
25. Meng E, Young JS, Brading AF. Spontaneous activity of mouse detrusor smooth muscle and the effects of the urothelium. Neurourol Urodyn 2008; 27: 79-87.
26. Shioyama R, Aoki Y, Ito H et al. Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. Am J Physiol Regul Integr Comp Physiol 2008; 295: R714-8.
27. Wang EC, Lee JM, Johnson JP, Kleyman TR, Bridges R, Apodaca G. Hydrostatic pressure-regulated ion transport in bladder uroepithelium. Am J Physiol Renal Physiol 2003; 285: F651-63.
28. Birder LA, Kanai AJ, de Groat WC et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 2001; 98: 13396-401.
29. Birder LA, Nakamura Y, Kiss S et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002; 5: 856-60.
30. Everaerts W, Gevaert T, Nilius B, De Ridder D. On the origin of bladder sensing: Tr(i)ps in urology. Neurourol Urodyn 2008; 27: 264-73.
31. Lips KS, Wunsch J, Zarghooni S et al. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol 2007; 51: 1042-53.
32. Chuang YC, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 1353-7.
33. Abrams PH, Farrar DJ, Turner-Warwick RT et al. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121: 640-2.
34. de Nunzio C, Franco G, Rocchegiani A et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003; 169: 535-9.
35. Seki N, Kai N, Seguchi H et al. Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology 2006; 67: 306-10.
36. Van Venrooij GE, Van Melick HH, Eckhardt MD et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002; 168: 605-9.
37. Housami F, Abrams P. Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep 2008; 9: 284-90.
38. Price DA, Ramsden PD, Stobbart D et al. The unstable bladder and prostatectomy. Br J Urol 1980; 52: 529-31.
39. Seaman EK, Jacobs BZ, Blaivas JG et al. Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment. J Urol 1994; 152: 935-7.
40. Steers WD, De Groat WC. Effect of bladder outlet obstruction on micturition reflex pathways in the rat. J Urol 1988; 140: 864-71.
41. Steers WD, Kolbeck S, Creedon D et al. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 1991; 88: 1709-15.
42. Caterina MJ, Schumacher MA, Tominaga M et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
43. Kim JC, Kim DB, Seo SI et al. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int 2004; 94: 915-8.
44. Baker SA, Hatton WJ, Han J et al. Role of TREK-1 potassium channel in bladder overactivity after partial bladder outlet obstruction in mouse. J Urol 2010; 183: 793-800.
45. Baker SA, Hennig GW, Han J et al. Methionine and its derivatives increase bladder excitability by inhibiting stretch-dependent K(+) channels. Br J Pharmacol 2008; 153: 1259-71.
46. Salkoff L, Butler A, Ferreira G et al. High-conductance potassium channels of the SLO family. Nat Rev Neurosci 2006; 7: 921-31.
47. Herrera GM, Pozo MJ, Zvara P et al. Urinary bladder instability induced by selective suppression of the murine small conductance calcium-activated potassium (SK3) channel. J Physiol 2003; 551 (Pt 3): 893-903.
48. Meredith AL, Thorneloe KS, Werner ME et al. Overactive bladder and incontinence in the absence of the BK large conductance Ca2+-activated K+ channel. J Biol Chem 2004; 279: 36746-52.
49. Petkov GV, Bonev AD, Heppner TJ et al. Beta1-subunit of the Ca2+-activated K+ channel regulates contractile activity of mouse urinary bladder smooth muscle. J Physiol 2001; 537 (Pt 2): 443-52.
50. Thorneloe KS, Knorn AM, Doetsch PE et al. Smallconductance, Ca(2+) -activated K+ channel 2 is the key functional component of SK channels in mouse urinary bladder. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1737-43.
51. Thorneloe KS, Meredith AL, Knorn AM et al. Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder. Am J Physiol Renal Physiol 2005; 289: F604-10.
52. Darblade B, Behr-Roussel D, Oger S et al. Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology 2006; 68: 442-8.
53. Malysz J, Buckner SA, Daza AV et al. Functional characterization of large conductance calcium-activated K+ channel openers in bladder and vascular smooth muscle. Naunyn Schmiedeberg's Arch Pharmacol 2004; 369: 481-9.
54. Pinna C, Sanvito P, Bolego C et al. Effect of the ATP-sensitive potassium channel opener Z M226600 on cystometric parameters in rats with ligature-intact, partial urethral obstruction. Eur J Pharmacol 2005; 516: 71-7.
55. Kita M, Yunoki T, Takimoto K et al. Effects of bladder outlet obstruction on properties of Ca2+-activated K+ channels in rat bladder. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1310-9.
56. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002; 22: 133-45.
57. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 2003; 43: 1-5.
58. de Groat WC. The urothelium in overactive bladder: passive bystander or active participant? Urology 2004; 64(Suppl 1): 7-11.
59. Jiang LH, Kim M, Spelta V et al. Subunit arrangement in P2X receptors. J Neurosci 2003; 23: 8903-10.
60. North RA, Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 2000; 40: 563-80.
61. Cook SP, McCleskey EW. ATP, pain and a full bladder. Nature 2000; 407: 951-2.
62. Zhong Y, Banning AS, Cockayne DA et al. Bladder and cutaneous sensory neurons of the rat express different functional P2X receptors. Neuroscience 2003; 120: 667-75.
63. Kim JC, Yoo JS, Park EY et al. Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int 2008; 101: 371-5.
64. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002; 287: 356-9.
65. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complication. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
66. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16: 442-3.
67. Alberti KG, Zimmet P, Shaw J et al. The metabolic syndrome-a new worldwide definition. Lancet 2005 Sep 24-30; 366(9491): 1059-62.
68. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005; 29: 310-6.
69. Yu HJ, Liu CY, Lee KL, Lee WC, Chen THH. Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking. Urol Int 2006; 77: 327-33.
70. Lawrence JM, Lukacz ES, Liu IL, Nager CW, Luber KM. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabet Care 2007; 30: 2536-41.
71. Lee WC, Wu CC, Wu HP, Tai TY. Lower urinary tract symptoms and uroflowmetry in women with type 2 diabetes mellitus with and without bladder dysfunction. Urology 2007; 69: 685-90.
72. Lee WC. The impact of diabetes on the lower urinary tract dysfunction. JTUA 2009; 20: 155-61.
73. Liu RT, Chung MS, Lee WC et al. Prevalence of Overactive Bladder (OAB) and associated risk factors in 1, 359 patients with type 2 diabetes. Urology 2011; 78: 1040-5.
74. Steers WD. An enlarged prostate is diagnosed more often in patients with type 2 diabetes. Rev Urol 2002; 4: S7-18.
75. Liu G, Daneshgari F. Alterations in neurogenically mediated contractile responses of urinary bladder in rats with diabetes. Am J Physiol Renal Physiol 2005; 288: F1220-6.
76. Wang CC, Nagatomi J, Toosi KK et al. Diabetes-induced alternations in biomechanical properties of urinary bladder wall in rats. Urology 2009; 73: 911-5.
77. Tong YC, Cheng JT, Hsu CT. Alterations of M(2)-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder. Neurosci Lett 2006; 406: 216-21.
78. Cheng JT, Yu BC, Tong YC. Changes of M3-muscarinic receptor protein and mRNA expressions in the bladder urothelium and muscle layer of streptozotocin-induced diabetic rats. Neurosci Lett 2007; 423: 1-5.
79. Tong YC, Cheng JT. Alterations of M2, 3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J Urol 2007; 178: 1537-42.
80. Lee WC, Chien CT, Yu HJ, Lee SW. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J Urol 2008; 179: 2470-6.
81. Lee WC, Chuang YC, Chiang PH, Chien CT, Yu HJ, Wu CC. Pathophysiological studies of overactive bladder and bladder motor dysfunction in a rat model of metabolic syndrome. J Urol 2011; 186: 318-25.
82. Nobe K, Yamazaki T, Kumai T et al. Alterations of glucose-dependent and -independent bladder smooth muscle contraction in spontaneously hypertensive and hyperlipidemic rat. J Pharmacol Exp Ther 2008; 324: 631-42.
83. Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M. The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. Neurourol Urodyn 2010; 29: 1350-4.
84. Azadzoi KM, Shinde VM, Tarcan T et al. Increased leukotriene and prostaglandin release, and overactivity in the chronically ischemic bladder. J Urol 2003; 169: 1885-91.
85. Azadzoi KM, Radisavljevic ZM, Golabek T et al. Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder. J Urol 2010; 183: 362-9.
86. Yang SSD, Wang CC, Hsieh JH, Chen YT. α1-Adrenergic blockers in young men with primary bladder neck obstruction. J Urol 2002; 168: 571-4.
87. Kershen RT, Azadzoi KM, Siroky MB. Blood flow, pressure and compliance in the male human bladder. J Urol 2002; 168: 121-5.
88. Di Meo S, Venditti P. Mitochondria in exercise-induced oxidative stress. Biol Signals Recept 2001; 10: 125-40.
89. Kupelian V, McVary KT, Barry MJ et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston area community health survey. Urology 2009; 73: 950-7.
90. Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P. Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms. Urol Sci 2010; 21: 132-6.
91. McMahon SB, Dmitrieva N, Koltzenburg M. Visceral pain. Br J Anaesth 1995; 75.
92. Dmitrieva N, Shelton D, Rice ASC, McMahon SB. The role of nerve growth factor in a model of visceral inflammation. Neuroscience 1997; 78: 449-59.
93. Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N. The role of bladder afferent pathways in the bladder hyperactivity induced by intravesical administration of nerve growth factor. J Urol 2001; 165: 975-9.
94. Seki S, Sasaki K, Fraser MO et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 2002; 168: 2269-74.
95. Clemow DB, Steers WD, McCarty R, Tuttle JB. Altered regulation of bladder nerve growth factor and neurally mediated hyperactive voiding. Am J Physiol 1998; 275: R1279-86.
96. Andersson KE, Wein AJ. Pharmacology of lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004; 56: 581-631.
97. Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats-effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn 2008; 27: 88-95.
98. Schussler B. Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study. Urol Res 1990; 18: 349-52.
99. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175: 1773-6.
100. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008; 179: 2270-4.
101. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009; 56: 700-6.
102. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 103: 1668-72.
103. Tyagi P, Barclay D, Zamora R et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 2010; 42: 629-35.
104. Apostolidis A, Jacques TS, Freeman A et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008; 53: 1245-53.